drugset / Trial / NCT06541444
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
Phase 0
Recruiting
9 enrolled
Base Therapeutics (Shanghai) Co., Ltd.
Shanghai Pudong Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of NK520 in the treatment of relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.
Timeline
- Start
- 2024-07-01
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NK520 | Unknown | 3e+07 cells/kg | Intravenous |
| Subject | NK520 | Unknown | 6e+07 cells/kg | Intravenous |
| Subject | NK520 | Unknown | 9e+07 cells/kg | Intravenous |